Preclinical Phase

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) stock is surging after announcing encouraging preclinical data for pan coronavirus fully human monoclonal antibody (mAb) cocktail AR-701. The data show that the antibody is broadly reactive against the omicron and other COVID-19 variants, SARS (...

Oragenics Inc (NYSE: OGEN) has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) to enable Oragenics to pursue an intranasal vaccine designed against omicron variant.  The NRC cell expression technologies provide Oragenics with...

Vir Biotechnology Inc (NASDAQ: VIR) announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).  A significant reduction in plasma neutralizing activity...

Generation Bio Co (NASDAQ: GBIO) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development non-viral genetic medicine platform.  In mouse studies, rapid enzymatic synthesis...

ITeos Therapeutics Inc (NASDAQ: ITOS) posted new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021. Data at the ASH 2021 demonstrated the efficacy...

Anixa Biosciences Inc (NASDAQ: ANIX) announced the results of a genomic variant analysis conducted with its partner, MolGenie GmbH, on potential compounds to treat COVID-19.  The data indicate that the compounds in development should be effective against the Omicron...

Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy. Data were shared at the American Epilepsy Society Annual Meeting. In knockout mouse models of SLC13A5 deficiency,...

GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all mutations of the new Omicron coronavirus variant, citing new data from preclinical studies. The data shows that the...

Codiak BioSciences Inc (NASDAQ: CDAK) announced new preclinical data from its exoVACC exosome-based vaccine platform.  The data showed that the COVID-19 vaccine candidate generated a comprehensive immune response conferring both antibody and T cell-mediated immunity.  The data...

Oragenics Inc (NYSE: OGEN) announced the results from its hamster challenge study to evaluate the COVID-19 vaccine candidate. The study is assessing the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate. The study provided preclinical data for...

Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are trading higher after a Zack's Small Cap research note showed a $9 price target on the stock. The report is based on a probability-adjusted DCF model that considers potential future revenues from QN-247 and RAS-F. The Company is currently...

The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne).  Duchenne is a genetic disorder characterized by progressive muscle degeneration and weakness due to the...

Voyager Therapeutics Inc (NASDAQ: VYGR) announced preclinical data from a new vectorized anti-HER2 antibody program. Data showed that IV dosing of a proprietary AAV vector identified by the TRACER screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth...

The FDA has cleared Armata Pharmaceuticals Inc's (NYSE: ARMP) Investigational New Drug (IND) for Phase 1b/2a study of AP-SA02 in Staphylococcus aureus bacteremia.  Armata expects to begin the study by the end of 2021. The trial, dubbed diSArm, will be Armata's second...

VYNE Therapeutics Inc (NASDAQ: VYNE) announced preclinical data for VYN201, its pan-bromodomain and extra-terminal (BET) inhibitor. The data showed that VYN201 significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune...